title: Relapse of renal cell carcinoma with disappearance of HLA class I following hTERT peptide vaccination.
authors.affiliation: Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine, Toon, Japan. Electronic address: yasukawa@m.ehime-u.ac.jp.
authors.forename: M
authors.initials: M
authors.lastname: Yasukawa
authors.affiliation: Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine, Toon, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Ochi
authors.affiliation: Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine, Toon, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Fujiwara
mesh_terms: D000368:Aged; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D005260:Female; D015395:Histocompatibility Antigens Class I / Q000276:immunology*; D006801:Humans; D007680:Kidney Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D008175:Lung Neoplasms / Q000276:immunology / Q000556:secondary / Q000628:therapy; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000276:immunology* / Q000628:therapy; D010446:Peptide Fragments / Q000276:immunology*; D011379:Prognosis; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D019098:Telomerase / Q000276:immunology*
chemical_list: D019496:Cancer Vaccines; D015395:Histocompatibility Antigens Class I; D010446:Peptide Fragments; C509186:TERT protein, human; D019098:Telomerase